ストックスクリーナーアプリを入手
1.87
8.72%
0.15
アフターアワーズ：
1.88
0.010
+0.53%
前日終値:
$1.72
開ける：
$1.8311
24時間の取引高:
2.35M
Relative Volume:
1.13
時価総額：
$425.06M
収益：
-
当期純損益:
$-179.82M
株価収益率:
-1.406
EPS:
-1.33
ネットキャッシュフロー:
$-159.16M
1週間 パフォーマンス:
+12.65%
1か月 パフォーマンス:
+36.50%
6か月 パフォーマンス:
+111.08%
1年 パフォーマンス:
+74.77%
1日の値動き範囲:
$1.805
$1.88
1週間の範囲:
$1.635
$1.90
52週間の値動き範囲:
$0.6617
$1.90
Gossamer Bio Inc Stock (GOSS) Company Profile
GOSS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
1.87 | 390.96M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-14 | 開始されました | Scotiabank | Sector Outperform |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-04-05 | 再開されました | Wedbush | Outperform |
| 2023-07-27 | ダウングレード | UBS | Buy → Neutral |
| 2023-03-07 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | 開始されました | Guggenheim | Neutral |
| 2022-12-07 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2022-12-07 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-12-07 | ダウングレード | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | 開始されました | Goldman | Buy |
| 2022-09-21 | 開始されました | JP Morgan | Neutral |
| 2022-09-19 | 開始されました | Wedbush | Outperform |
| 2022-04-18 | 開始されました | Raymond James | Outperform |
| 2022-04-06 | 開始されました | UBS | Buy |
| 2022-01-10 | アップグレード | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-09-21 | 再開されました | Piper Sandler | Overweight |
| 2020-06-29 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-22 | 開始されました | Piper Sandler | Overweight |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2019-12-03 | 再開されました | BofA/Merrill | Buy |
| 2019-10-30 | 開始されました | Berenberg | Buy |
| 2019-03-05 | 開始されました | Barclays | Overweight |
| 2019-03-05 | 開始されました | BofA/Merrill | Buy |
| 2019-03-05 | 開始されました | Evercore ISI | Outperform |
| 2019-03-05 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Gossamer Bio Inc (GOSS) 最新ニュース
GOSS’s 2025 Market Dance: Up 86.05% – Time to Invest? - investchronicle.com
Is Gossamer Bio Inc. a good long term investmentBreakthrough capital growth - jammulinksnews.com
What drives Gossamer Bio Inc. stock priceTremendous portfolio expansion - jammulinksnews.com
What analysts say about Gossamer Bio Inc. stockJaw-dropping returns - jammulinksnews.com
Why Gossamer Bio Inc. stock attracts strong analyst attentionBig Return Stock Tips - Newser
What makes Gossamer Bio Inc. stock price move sharplyLow Volatility High Yield Stocks - Newser
Gossamer Bio Inc. Stock Analysis and ForecastFree Stock Chart Pattern Guide - jammulinksnews.com
How Gossamer Bio Inc. stock performs during market volatilityShort Term Risk Controlled Alerts - Newser
GOSS’s Stock Market Adventure: 30.77% YTD Growth Amidst Volatility - investchronicle.com
Scotiabank Initiates Gossamer Bio at Sector Outperform With $11 Price Target - MarketScreener
Gossamer Bio (NASDAQ:GOSS) Shares Down 3.2% – Time to Sell? - Defense World
Gossamer Bio, Inc.(NasdaqGS: GOSS) added to Russell 3000 Growth Index - MarketScreener
Gossamer Bio, Inc.(NasdaqGS: GOSS) added to Russell Microcap Index - MarketScreener
Gossamer Bio Approves 2019 Incentive Award Plan - TipRanks
Gossamer Bio Completes Enrollment for Phase 3 PROSERA Study of PAH Drug Seralutinib - Insider Monkey
Gossamer Bio Announces Completion of Enrollment in Registrationa - GuruFocus
Gossamer Bio (GOSS) Wraps Up Enrollment for Phase 3 PAH Study | GOSS Stock News - GuruFocus
Gossamer Bio Announces Completion Of Enrollment In Registrational Phase 3 PROSERA Study For The Treatment Of PAH - MarketScreener
Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH - The Joplin Globe
Gossamer Bio's Breakthrough PAH Drug Hits Major Milestone: 390 Patients Enrolled in Phase 3 Trial - Stock Titan
Squarepoint Ops LLC Has $65,000 Stake in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
Brokers Offer Predictions for Gossamer Bio FY2026 Earnings - Defense World
Two Sigma Investments LP Raises Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rul - GuruFocus
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | GOSS Stock News - GuruFocus
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule - marketscreener.com
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
HC Wainwright Increases Earnings Estimates for Gossamer Bio - Defense World
Cantor Fitzgerald Forecasts Gossamer Bio FY2025 Earnings - Defense World
Analyze Gossamer Bio Inc (NASDAQ: GOSS) Before Investing. - Stocksregister
Price T Rowe Associates Inc. MD Has $59,000 Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
Gossamer Bio, Inc. (NASDAQ:GOSS) Q1 2025 Earnings Call Transcript - MSN
Wedbush Reiterates “Outperform” Rating for Gossamer Bio (NASDAQ:GOSS) - Defense World
The Goldman Sachs Group Raises Gossamer Bio (NASDAQ:GOSS) Price Target to $8.00 - Defense World
GOSS Stock Update: Analyst Reiterates Outperform Rating | GOSS S - GuruFocus
Gossamer Bio’s Earnings Call: Mixed Sentiments and Strategic Moves - TipRanks
Gossamer Bio (GOSS): Goldman Sachs Raises Price Target to $8.00 - GuruFocus
Cantor Fitzgerald maintains Overweight on Gossamer Bio stock By Investing.com - Investing.com Nigeria
Gossamer Bio Inc (GOSS) 財務データ
収益
当期純利益
現金流量
EPS
4.91%
0.25%
大文字化:
|
ボリューム (24 時間):